KROSNasdaqPharmaceutical PreparationsFiscal year ends December 31
Keros Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 3, 2026
$11.06+0.40 (+3.75%)
Close on Oct 19, 2026
- Market cap
- $218.99M
- P/E (TTM)
- –
- Dividend yield
- –
Keros Therapeutics, Inc. revenue by segment
By business segment
By product or service
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|
| License revenue | $205.36M | $3.00M | $0 | $0 | $20.10M | 84.2% | +6745.2% |
| License revenue | $205.36M | $0 | – | – | – | 84.2% | – |
| Service and other revenue | $38.71M | $550.00K | $151.00K | $0 | $0 | 15.9% | +6937.5% |
| Service revenue | $38.50M | $0 | – | – | – | 15.8% | – |
By region
From the segment and revenue-disaggregation notes of Keros Therapeutics's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.